Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Siegismund, CS; Escher, F; Lassner, D; Kühl, U; Gross, U; Fruhwald, F; Wenzel, P; Münzel, T; Frey, N; Linke, RP; Schultheiss, HP.
Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis.
Eur J Heart Fail. 2018; 20(4):751-757 Doi: 10.1002/ejhf.1039 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Fruhwald Friedrich

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

To evaluate the influence of endomyocardial biopsy (EMB)-proven intramyocardial inflammation on mortality in patients with cardiac transthyretin amyloid (ATTR) or amyloid light-chain (AL) amyloidosis. We included 54 consecutive patients (mean age 68.83 ± 9.59 years; 45 men) with EMB-proven cardiac amyloidosis. We followed up patients from first diagnostic biopsy to as long as 36 months (mean 11.5 ± 12 months) and compared their outcome with information on all-cause mortality with or without proof of inflammation on EMB. Intramyocardial inflammation was assessed by quantitative immunohistology. Patients suffering from amyloidosis revealed a significant poor prognosis with proof of intramyocardial inflammation in contrast to those without inflammation (log-rank P = 0.019). Re-grouping of patients indicated AL amyloidosis to have a significant impact on all-cause mortality (log-rank P = 0.012). The detailed subgroup analysis showed that patients suffering from AL amyloidosis with intramyocardial inflammation have a significantly worse prognosis compared with AL amyloidosis without inflammation and ATTR with or without inflammation, respectively (log-rank P = 0.014, contingency Fisher's exact test, P = 0.008). Our study reports for the first time a high incidence (48.1%) of intramyocardial inflammation in a series of patients with EMB-proven cardiac amyloidosis and could show that in patients with AL amyloidosis, intramyocardial inflammation correlated significantly with increased mortality. Our data have a direct clinical impact because one can hypothesize that additional immunomodulating/anti-inflammatory treatment regimens in patients with biopsy-proven inflammation of heart muscle tissue could be beneficial for patients suffering from cardiac AL amyloidosis. © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Find related publications in this database (Keywords)
© Med Uni Graz Impressum